Spiroindoline pyrrolopyrrole triones NRF2-β-TrCP inhibitors for fatty liver treatment
Summary
USPTO granted Patent US12590100B2 to researchers from Universidad Autonoma de Madrid and CSIC for spiroindoline pyrrolopyrrole trione compounds that inhibit the NRF2-β-TrCP interaction for treating fatty liver disease. The patent covers 3 claims and relates to therapeutic applications for chronic inflammation and oxidative stress-related liver conditions.
What changed
The USPTO issued Patent US12590100B2 covering tetrahydro-spiroindoline-pyrrolopyrrole-trione inhibitors of the NRF2-β-TrCP interaction. The invention (inventors: Cuadrado Pastor et al.) provides compounds with general formula I and derivative salts for treating NRF2-related diseases caused by chronic inflammation and oxidative stress, specifically fatty liver disease. The patent classifies under CPC codes C07D 487/20, A61P 1/16, and G01N 33/5008.\n\nPatent holders and licensees seeking to develop these compounds for therapeutic use must obtain authorization from patent owners. Generic drug manufacturers should consider freedom-to-operate implications before commercial development. Research institutions may reference this patent when pursuing related NRF2 pathway therapeutics.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Tetrahydro-spiroindoline-pyrrolopyrrole-triones inhibitors of the NRF2-β-TrCP interaction for use in the treatment of fatty liver disease
Grant US12590100B2 Kind: B2 Mar 31, 2026
Inventors
Antonio Cuadrado Pastor, Raquel Fernandez Gines, Jose Antonio Encinar, Rafael Leon Martinez, Juan Felipe Franco Gonzalez, Manuela Garcia Lopez, Maria Isabel Rodriguez Franco, Ana Isabel Rojo Sanchis
Abstract
The present invention relates to NRF2-βTrCP interaction inhibitors with general formula I and its derivate salts for use in the treatment of NRF2-related diseases caused by chronic inflammation and oxidative stress. More specifically the present invention relates to NRF2-βTrCP interaction inhibitors with specific formula I and its derivate salts for treating diseases of the liver related with chronic inflammation and oxidative stress, such as fatty liver disease.
CPC Classifications
C07D 487/20 A61P 1/16 G01N 33/5008
Filing Date
2022-01-13
Application No.
18027990
Claims
3
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.